N-(2,4-Difluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea | 286370-24-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(2,4-Difluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea
• 英文别名: 1-(2,4-Difluorophenyl)-3-(4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea；1-(2,4-difluorophenyl)-3-[4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]urea
• CAS: 286370-24-9
• 化学式: C₂₃H₁₈F₂N₄O₄
• 分子量: 452.417
• InChiKey: FMQNPBJPCTVJNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-氯-6,7-二甲氧基喹唑啉 在 四丁基溴化铵 、 三乙胺 、 sodium hydroxide 作用下， 以 氯仿 、 水 、 丁酮 为溶剂， 生成 N-(2,4-Difluorophenyl)-N'-{4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}urea
  参考文献：
  名称：

  Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors

  摘要：

  Three series of 6,7-dimethoxyquinazoline derivatives substituted in the 4-position by aniline, N-methylaniline and aryloxy entities, targeting EGFR and VEGFR-2 tyrosine kinases, were designed and synthesized. Pharmacological activities of these compounds have been evaluated for their enzymatic inhibition of VEGFR-2 and EGFR and for their antiproliferative activities on various cancer cell lines. We have studied the impact of the variation in the 4-position substitution of the quinazoline core. Substitution by aryloxy groups led to new compounds which are selective inhibitors of VEGFR-2 enzyme with IC50 values in the nanomolar range in vitro. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.137

文献信息

• Quinoline derivatives and quinazoline derivatives
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20040209905A1

  公开（公告）日：2004-10-21

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: 1 wherein X and Z each independently represent CH or N; R 1 to R 3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R 4 represents H; R 5 to R 8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R 5 to R 8 do not simultaneously represent H; R 9 and R 10 represent H, alkyl, or alkylcarbonyl; and R 11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明揭示了由式（I）表示的化合物，以及其药学上可接受的盐和溶剂和包含所述化合物的制药组合物：1其中X和Z各自独立地表示CH或N; R1至R3表示H、取代烷氧基、未取代烷氧基或类似物; R4表示H; R5至R8表示H、卤素、烷基、烷氧基、烷基硫基、硝基或氨基，但要求R5至R8不同时表示H; R9和R10表示H、烷基或烷基羰基; 而R11表示烷基、烯基、炔基或芳基烷基。
• Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1384712A1

  公开（公告）日：2004-01-28

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: wherein X and Z each independently represent CH or N; R1 to R3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R4 represents H; R5 to R8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R5 to R8 do not simultaneously represent H; R9 and R10 represent H, alkyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明公开了式(I)代表的化合物及其药学上可接受的盐和溶液以及包含所述化合物的药物组合物： 其中X和Z各自独立地代表CH或N；R1至R3代表H、取代的烷氧基、未取代的烷氧基或类似物；R4代表H；R5至R8代表H、卤素、烷基、烷氧基、烷硫基、硝基或氨基，但R5至R8不同时代表H；R9和R10代表H、烷基或烷基羰基；R11代表烷基、烯基、炔基或芳烷基。
• QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1153920B1

  公开（公告）日：2003-10-29
• US6797823B1
  申请人：——

  公开号：US6797823B1

  公开（公告）日：2004-09-28
• US7169789B2
  申请人：——

  公开号：US7169789B2

  公开（公告）日：2007-01-30